m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00185)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
ATF4
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | 253J cell line | Homo sapiens |
Treatment: siFTO 253J cells
Control: 253J cells
|
GSE150239 | |
Regulation |
|
logFC: -1.42E+00 p-value: 2.68E-47 |
More Results | Click to View More RNA-seq Results |
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Wilms tumor 1-associating protein (WTAP) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by WTAP | ||
Cell Line | mice hepatocyte | Mus musculus |
Treatment: Wtap Hknockout mice hepatocyte
Control: Wtap flox/flox mice hepatocyte
|
GSE168850 | |
Regulation |
|
logFC: 7.14E-01 p-value: 2.43E-02 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | Myocardial infarction (MI) is one of the leading causes of death. WTAP promoted myocardial I/R injury through promoting ER stress and cell apoptosis by regulating m6A modification of Cyclic AMP-dependent transcription factor ATF-4 (ATF4) mRNA. H/R effects on ER stress and apoptosis were all blocked by silencing of WTAP, promoted by WTAP overexpression, and ameliorated by administration of ER stress inhibitor, 4-PBA. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Acute myocardial infarction | ICD-11: BA41 | ||
Cell Process | Endoplasmic reticulum stress | |||
Cell apoptosis | ||||
In-vitro Model | AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 |
In-vivo Model | Left anterior descending coronary artery (LAD) was ligated for 20 minutes, followed by 48 h reperfusion. Controls underwent same procedures except LAD ligation. WTAP shRNA vector or its negative control (shNC) was injected into the left ventricular anterior wall 24 h before I/R. A pressure volume catheter was used for cardiac function assay. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 4 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Colorectal cancer [ICD-11: 2B91]
In total 4 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Asparagine inhibitor | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Chloroquine | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 3 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | Meclofenamate sodium | Approved | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 4 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Responsed Disease | Colorectal cancer [ICD-11: 2B91] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Drug | CB-839 | Phase 2 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Acute myocardial infarction [ICD-11: BA41]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | Myocardial infarction (MI) is one of the leading causes of death. WTAP promoted myocardial I/R injury through promoting ER stress and cell apoptosis by regulating m6A modification of Cyclic AMP-dependent transcription factor ATF-4 (ATF4) mRNA. H/R effects on ER stress and apoptosis were all blocked by silencing of WTAP, promoted by WTAP overexpression, and ameliorated by administration of ER stress inhibitor, 4-PBA. | |||
Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Endoplasmic reticulum stress | |||
Cell apoptosis | ||||
In-vitro Model | AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 |
In-vivo Model | Left anterior descending coronary artery (LAD) was ligated for 20 minutes, followed by 48 h reperfusion. Controls underwent same procedures except LAD ligation. WTAP shRNA vector or its negative control (shNC) was injected into the left ventricular anterior wall 24 h before I/R. A pressure volume catheter was used for cardiac function assay. | |||
Asparagine inhibitor
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Chloroquine
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Meclofenamate sodium
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Rapamycin
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
CB-839
[Phase 2]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. Cyclic AMP-dependent transcription factor ATF-4 (ATF4) transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
GLS-IN-968
[Investigative]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | In colorectal cancer, Glutaminolysis inhibition upregulated ATF4 expression in an m6A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Determined the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 transcriptionally upregulated DDIT4 to suppress Cyclic AMP-dependent transcription factor ATF-4 (ATF4), which induced pro-survival autophagy during glutaminolysis inhibition. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
Pathway Response | mTOR signaling pathway | hsa04150 | ||
Cell Process | RNA decay | |||
Cell growth and death | ||||
Cell autophagy | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
References